| Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis (NCT07750574) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2026-11-01 |
| Clinical Study on Drug Interactions of Flonoltinib Maleate Tablets (NCT07768111) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2026-10-30 |
| Phase I Clinical Study of ZL-65 Tablet in Healthy Adult Participants in China (NCT07757152) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2026-07-23 |
| Mass Balance Study of [14C] Flonoltinib Maleate (NCT07612306) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2026-07-06 |
| A Clinical Study of ZL-85FA Tablets (NCT07339748) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2026-06-30 |
| A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Intermediate to High Risk Myelofibrosis (NCT07443306) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2026-03-18 |
| A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis (NCT07317700) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2026-02-13 |
| A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis (NCT07193589) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2026-02-03 |
| Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera (NCT07232290) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2025-09-23 |
| A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma (NCT07011056) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2025-07-18 |
| A Pharmacokinetic Study of the Food Effect on Flonoltinib Maleate Tablets (NCT07193576) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2024-08-04 |
| A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors (NCT06431243) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2024-05-08 |
| A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis (NCT06457425) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2024-05-06 |
| A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma (NCT06485219) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2024-04-14 |
| Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (NCT06484829) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2024-03-25 |
| ZL-82 Double-blind Clinical Trial (NCT06432738) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2024-03-19 |
| A Phase I Clinical Study of Flonoltinib Maleate Tablets in Healthy Subjects (NCT06387966) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2024-03-18 |
| Study of Flonoltinib Maleate Tablets in the Treatment of Severe Novel Coronavirus (COVID-19) Infection (NCT05713279) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2023-05-23 |
| Phase I Clinical Study of ZL-82 Tablets (NCT06055023) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2023-04-09 |
| Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) (NCT05563844) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2022-11-08 |
| Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative (NCT05153343) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2021-12-27 |
| Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant (NCT05526313) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2020-08-10 |